1. Home
  2. RNTX vs FTHM Comparison

RNTX vs FTHM Comparison

Compare RNTX & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc. Common Stock

BUY

Current Price

$1.55

Market Cap

38.9M

Sector

Health Care

ML Signal

BUY

Logo Fathom Holdings Inc.

FTHM

Fathom Holdings Inc.

HOLD

Current Price

$1.24

Market Cap

37.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
FTHM
Founded
2001
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
37.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RNTX
FTHM
Price
$1.55
$1.24
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$10.00
$2.50
AVG Volume (30 Days)
184.8K
112.6K
Earning Date
11-14-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$421,612,000.00
Revenue This Year
N/A
$30.07
Revenue Next Year
N/A
$14.66
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.78
52 Week Low
$1.04
$0.65
52 Week High
$3.50
$3.37

Technical Indicators

Market Signals
Indicator
RNTX
FTHM
Relative Strength Index (RSI) 58.01 48.02
Support Level $1.34 $1.16
Resistance Level $1.58 $1.26
Average True Range (ATR) 0.10 0.07
MACD 0.01 0.02
Stochastic Oscillator 87.50 47.06

Price Performance

Historical Comparison
RNTX
FTHM

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About FTHM Fathom Holdings Inc.

Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.

Share on Social Networks: